VWR Acquires United Biochemicals
News Jul 05, 2013
Based in Sanborn, New York and founded in 1996, United Biochemicals manufactures and supplies high purity buffers and biochemicals for research, development and manufacturing processes to biotech, pharmaceutical, cell culture media and medical diagnostic industries.
"United Biochemicals is a strong compliment to VWR's growing life sciences portfolio as VWR continues to make strategic investment into our business," said Manuel Brocke-Benz, President and CEO of VWR. "United Biochemicals' manufacturing expertise, combined with VWR's existing platform of chemical manufacturing assets, enhances our current offering to our biotech and pharmaceutical customers and strengthens our position in the industry."
"We are excited to join a trusted, global brand like VWR," shared Fayyaz Hussain, President of United Biochemicals. "This acquisition will allow United Biochemicals to leverage VWR's global sales and marketing organization to grow our business."
Financial details of this acquisition remain confidential.
‘Mini Tumors’ from Patient Samples Could Help Personalize Cancer Drug TreatmentNews
Testing cancer drugs on miniature replicas of a patient’s tumour could help doctors tell in advance which treatments will work, a major new study reports.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE